Search research articles
Contact Us
Filters
Showing results (31-40 of 78) with videos related to
Page
of 8
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 15, 2014
Distress among caregivers of phase I trial participants: a cross-sectional study
Elizabeth R Kessler, Angela Moss, S Gail Eckhardt, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 24, 2017
Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy
Chad G Rusthoven, Ryan M Lanning, Bernard L Jones, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 9, 2018
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
Tejas Patil, Derek E Smith, Paul A Bunn, et al.
Investigational New Drugs
|
April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors
Jennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Journal of Clinical Pharmacology
|
December 23, 2024
Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT<sub>3</sub> Antagonist Antiemetic Drugs
Lauren E Thompson, Avisek Ghimire, Xia Wen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer
Benjamin Levy, Alexander Spira, Daniel Becker, et al.
Oral Oncology
|
January 17, 2015
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno, Julie E Bauman, Charles Weissman, et al.
European Journal of Clinical Pharmacology
|
September 17, 2018
Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients
Mustafa E Ibrahim, Cara Chang, Yichun Hu, et al.
Molecular Carcinogenesis
|
December 22, 2018
Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas
Ariel L Hernandez, Ying Wang, Hilary L Somerset, et al.
Clinical Colorectal Cancer
|
April 28, 2016
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma
Daniel W Bowles, Mark Kochenderfer, Allen Cohn, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 78) with videos related to
Sort By:
Page
of 8
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 15, 2014
Distress among caregivers of phase I trial participants: a cross-sectional study
Elizabeth R Kessler, Angela Moss, S Gail Eckhardt, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 24, 2017
Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy
Chad G Rusthoven, Ryan M Lanning, Bernard L Jones, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 9, 2018
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
Tejas Patil, Derek E Smith, Paul A Bunn, et al.
Investigational New Drugs
|
April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors
Jennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Journal of Clinical Pharmacology
|
December 23, 2024
Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT<sub>3</sub> Antagonist Antiemetic Drugs
Lauren E Thompson, Avisek Ghimire, Xia Wen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer
Benjamin Levy, Alexander Spira, Daniel Becker, et al.
Oral Oncology
|
January 17, 2015
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno, Julie E Bauman, Charles Weissman, et al.
European Journal of Clinical Pharmacology
|
September 17, 2018
Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients
Mustafa E Ibrahim, Cara Chang, Yichun Hu, et al.
Molecular Carcinogenesis
|
December 22, 2018
Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas
Ariel L Hernandez, Ying Wang, Hilary L Somerset, et al.
Clinical Colorectal Cancer
|
April 28, 2016
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma
Daniel W Bowles, Mark Kochenderfer, Allen Cohn, et al.
Page
of 8